Mumbai-based personal fairness agency Somerset Indus Capital Companions right now introduced the profitable fund increase of its third fund, Fund III, at $288 million, exceeding its preliminary goal of $250 million.

The oversubscribed noticed conviction from each current and new Restricted Companions for Somerset’s differentiated healthcare-focused, impact-aligned funding technique.

The agency mentioned that the fund witnessed participation from a various group of worldwide institutional buyers, together with Growth Finance Establishments (DFIs), international funding corporations, home monetary establishments, insurance coverage corporations, funds of funds, household workplaces, and affect buyers throughout Europe, the USA and South-East Asia.

With Fund III, Somerset will proceed to deal with addressing healthcare entry gaps throughout India’s “lacking center,” significantly in Tier II and Tier III markets. The fund will put money into scalable healthcare companies delivering reasonably priced, accessible high quality care throughout healthcare supply, prescription drugs, medical gadgets, diagnostics, and allied sectors.

“The profitable fund increase is a robust endorsement of our technique and execution capabilities. We’re grateful for the continued belief of our Restricted Companions who share our conviction that affect and monetary efficiency could be mutually reinforcing,” mentioned Avinash Kenkare, Accomplice, Somerset Indus Capital Companions.

“India’s healthcare ecosystem is present process a structural transformation, significantly past the metros. Fund III positions us to deepen our presence in underserved markets and accomplice with entrepreneurs constructing scalable healthcare platforms. We stay dedicated to delivering measurable affect alongside sustainable monetary returns,” added Mayur Sirdesai, Accomplice, Somerset Indus Capital Companions.

Somerset sometimes invests between $15 million and $40 million per portfolio firm. Nevertheless, by co-investment syndication alongside its robust LP community, the agency has the pliability to take part in considerably bigger transactions within the vary of $60-80 million.

The extra capital will allow it to assist bigger and extra structurally transformative alternatives throughout areas akin to preventive care and OPD-linked insurance coverage, healthcare financing, embedded insurance coverage options, value-driven generics, India-focused medtech innovation, and diagnostics platforms bettering accessibility and standardisation past metro markets.

By fund III, Somerset has made three investments, i.e. Cyrix Healthcare (MedTech servicing), Printmann Offset (pharmaceutical packaging), and NU Hospitals (a nephrology and urology centered single-specialty hospital chain).